Most Read Articles
02 Jul 2019
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approval. Supplemental approvals may have occurred since the original approval date.
05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).

Metformin improves peripheral insulin sensitivity in overweight adolescents with T1D

13 Jul 2019

Treatment with metformin may improve whole-body and peripheral insulin resistance (IR) in youth who are overweight/obese with type 1 diabetes (T1D), according to a study.

This double-blind, multicentre, placebo-controlled clinical trial was conducted at eight sites of the T1D Exchange Clinic Network and included a subset of individuals aged 12–19 years with T1D from a larger trial. The inclusion criteria were body mass index ≥85th percentile, HbA1c 7.5–9.9 percent and insulin dosing ≥0.8 U/kg/d.

Participants were randomly assigned to 3 months of metformin (n=19) or placebo (n=18) and underwent a three-phase hyperinsulinaemic euglycaemic clamp with glucose and glycerol isotope tracers to examine tissue-specific IR before and after treatment.

The authors measured peripheral insulin sensitivity, endogenous glucose release and lipolysis rate before and after metformin or placebo therapy.

Differences in change in insulin sensitivity were detected in favour of the metformin vs the placebo arm vis-à-vis whole-body IR (change in glucose infusion rate, 1.3 mg/kg/min, 0.1–2.4; p=0.03) and peripheral IR (change in metabolic clearance rate, 0.923 dL/kg/min, –0.002 to 1.867; p=0.05).

Metformin showed no influence on insulin suppression of endogenous glucose release (p=0.12). In addition, adipose IR could not be measured with traditional methods in this highly IR population.

“T1D in adolescence is characterized by insulin deficiency and IR, both thought to increase cardiovascular disease risk,” the authors said. “We previously demonstrated that adolescents with T1D have adipose, hepatic and muscle IR, and that metformin lowers daily insulin dose, suggesting improved IR.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Jul 2019
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approval. Supplemental approvals may have occurred since the original approval date.
05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).